Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
5 Jun 2015

Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma

Prof Gary Schwartz - Columbia University, New York, USA
Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma ( Prof Gary Schwartz - Columbia University, New York, USA )
1 Jun 2015

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
30 May 2015

ecancermedicalscience editor's choice for February 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
3 Mar 2015

The role of health economics in cancer outcomes research

Prof Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden
The role of health economics in cancer outcomes research ( Prof Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden )
6 Jan 2015

Biobanking biological materials and linkage to clinical information

Dr Peter Riegman, Erasmus Medical Center, Rotterdam, The Netherlands
Biobanking biological materials and linkage to clinical information ( Dr Peter Riegman, Erasmus Medical Center, Rotterdam, The Netherlands )
6 Jan 2015

2nd EurocanPlatform translational research course is good for networking

Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal
2nd EurocanPlatform translational research course is good for networking ( Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal )
6 Jan 2015

Reasons to attend the EurocanPlatform translational research course 2015

Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany
Reasons to attend the EurocanPlatform translational research course 2015 ( Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany )
6 Jan 2015

Immunotherapy of cancer: recent progress and future challenges

Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden
Immunotherapy of cancer: recent progress and future challenges ( Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015

Epigenome deregulation in cancer

Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France
Epigenome deregulation in cancer ( Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France )
6 Jan 2015

Aims and successes of the 2nd EurocanPlatform project translational research course

Christina von Gertten, Karolinska Institutet, Stockholm, Sweden
Aims and successes of the 2nd EurocanPlatform project translational research course ( Christina von Gertten, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015

New approaches and new partnership models for biomarker based clinical research

Dr Denis Lacombe, EORTC, Brussels, Belgium
New approaches and new partnership models for biomarker based clinical research ( Dr Denis Lacombe, EORTC, Brussels, Belgium )
6 Jan 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation